GANX — Gain Therapeutics Share News
0.000.00%
Last trade - 00:00Gain Therapeutics Inc expected to post a loss of 29 cents a share - Earnings Preview
Brief: Gain Therapeutics Announces Positive Results From Single Ascending Dose Part Of The Phase 1 Clinical Trial Of GT-02287
Brief: Gain Therapeutics Appoints Gene Mack As CFO
Gain Therapeutics Inc reports results for the quarter ended in December - Earnings Summary
Gain Therapeutics Inc expected to post a loss of 32 cents a share - Earnings Preview
Brief: Gain Therapeutics Announces Initiation Of MAD Part Of Phase 1 Clinical Trial Of Gt-02287
U.S. STOCKS ON THE MOVE-J.B. Hunt, Synopsys, DoorDash
U.S. STOCKS ON THE MOVE-Wayfair Inc, Remitly Global, Monopar Therapeutics
Brief: Gain Receives Notice Of Finance Chief Evan Ballantyne's Resignation
U.S. STOCKS ON THE MOVE-Coty, Planet Fitness, Quanta Services
Gain Therapeutics falls after CFO resigns
U.S. STOCKS ON THE MOVE-Adobe, United Parcel Service, ZeroFox Holdings
U.S. STOCKS ON THE MOVE-New York Community Bancorp, Rallybio, Willis Towers Watson
Brief: Gain Therapeutics’ GT-02287 Completely Restores Motor Function In Mouse Models Of Parkinson’s Disease
Gain Therapeutics climbs as Parkinson's therapy shows positive results
Brief: Gain Therapeutics Announces Preclinical Data Showing Restoration Of Enzymatic Function With Novel Allosteric Regulators In Gm1 Gangliosidosis Model
U.S. STOCKS ON THE MOVE-Celanese, CRH, Symbotic
Brief: Gain Therapeutics Announces Proposed Public Offering
Brief: Gain Therapeutics Announces Dosing Of First Two Subjects In Phase 1 Clinical Trial Of Gt-02287